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Martin Luther King Jr once said “We may have all come on different ships, but we're in the 
same boat now“. However, more than fifty years on, inequalities exist in healthcare and 
cancer outcomes vary greatly between different racial and socioeconomic groups1. This is
largely due to late presentation leading to less radical treatment in these groups2. In the US,
individuals from African---American populations are less likely to have medical insurance or a 
regular primary care physician3,4. Lung cancer  Low Dose Computed Tomography  (LDCT) 
screening in the National Lung Cancer Screening Trial (NLST)5 had a clinically and statistically 
significant impact on lung cancer specific and all cause mortality when compared to chest 
radiograph (CXR) alone. However, whether LDCT screening has the same effect in all racial 
groups had not yet been evaluated.
Lung cancer LDCT screening aims to detect lung cancers earlier in order to improve radical 
treatment rates and in turn improve long term survival and quality of life. However, 
individuals from non---White racial groups have been shown to have a reduced likelihood of 
undergoing curative surgery even after racial segregation and insurance coverage are 
accounted for6. It is likely, therefore that in addition to tobacco use and socioeconomic 
status (SES), factors such as health beliefs, trust in healthcare and difficult access to 
healthcare may contribute to delayed presentation.
Tanner and colleagues, in this issue of the Journal, have shown that the reduction in lung 
cancer specific mortality caused by LDCT screening was more pronounced in Blacks than 
Whites (HR 0.61 in Blacks vs. 0.86 in Whites) though the risk of death from lung cancer was 
almost doubled in Black compared with White current smokers (HR 4.10 vs. 2.25). This 
improved benefit was seen despite the fact that Black NLST participants had more features
associated with socioeconomic deprivation such as lower education and unmarried status, 
though SES as a variable was not reported. They also show that when stratifying by race, all 
cause mortality was significantly reduced by LDCT compared with CXR in Blacks but not 
Whites.
The authors propose this to be primarily due to the improved access to healthcare brought 
about by screening in this group (and hence was more pronounced in LDCT group than CXR 
group as the former was more sensitive in picking up findings that would result in regular 
healthcare consultations). In fact, they note that death from infections and coronary disease 
was also reduced in the LDCT screening group compared with the CXR group. It is not clear 
whether this effect is related to particular strategies or protocols held by the different 
screening centres and further evaluation of this would be of utmost interest.
This study has obvious strengths in that it evaluates the impact of screening in different 
racial groups in a very powerful data set, and to date, NLST has the richest set of data in the 
field. However, the authors acknowledge that approximately 90% of NLST participants were 
White and this is clearly not representative of the US population as a whole. Certainly, the 
2010 US national census data report an excess of 12% of the US population to be Black or 
African---American, three times the proportion within NLST participants7. It is also difficult to 
separate the deprivation effect from the race effect. The present study reports significantly 
increased correlates of deprivation within the Black study participants as compared with 
Whites, suggesting that most Blacks in the study were from low SES groups, whilst most 
Whites were not. Therefore, the differences in outcomes in the two groups may be subject 
to confounding from SES. A study comparing the effect of outcomes in different racial
groups after adjusting for SES is needed to distinguish such outcomes. Nonetheless, a study 
in lung cancer LDCT screening with these numbers of Black participants has not been done 
to date, and with these limitations in mind, much can be inferred from this study.
NLST used age and smoking criteria to determine eligibility to screening, though many risk 
prediction tools now exist that allow more sophisticated methods of selection of high---risk 
participants, and many of these place great value on race as a predictor of lung cancer risk8. 
Certainly, the PLCOm2012 gives varying risk scores, depending on race. For example, a White 
60 year old male, high school graduate, with emphysema, who smoked 20 cigarettes a day 
for 30 years until 10 years ago would have a lung cancer probability of 0.014. A Black male 
with the same risk factors would score 0.020 and would meet the risk entry criteria for 
screening, while the White male would not. Use of such scores may help to reduce 
inequalities by acknowledging the higher risk in some racial groups.
Selection is only one part of the problem, and improving uptake and adherence to screening 
is also of great importance. Certainly Blacks and current smokers are acknowledged to have 
lower risk perception of lung cancer9 and smokers and individuals from low SES groups have
shown poor participation in lung cancer screening studies10. Non---adherence to lung cancer
screening has been shown to be associated with African---American race, less than high school 
education and false positive screening results11. Studies in prostate and bowel screening 
modalities have also shown an association between non---adherence and current smokers 
and individuals with chronic bronchitis12.
Recruitment methods in NLST were highly variable across the different screening centres, 
particularly with respect to attempts to recruit participants from socioeconomically deprived 
communities by community outreach programmes13. Success with such programmes was 
poor with 53 out of 79 of such programmes failing to recruit or recruiting badly. Six centres 
implemented programmes to specifically target African---American minorities in a variety of 
ways and though success rate by ethnicity is not currently reported, it is acknowledged that 
some institutions used community outreach programmes to increase their recruitment of 
minority groups. However, 17 of the 23 community outreach programmes within these six 
institutions failed to recruit or recruited badly implying that limited success was achieved in 
minority groups. Furthermore it was noted that outreach programmes were very 
inexpensive at a median cost per recruit of $4 compared with mass media ($79 per recruit) 
and direct mail ($101 per recruit). Of these, television advertising has been reported to most 
significantly increase the cost of recruitment14.
Tanner and Colleagues are to be commended on their study which demonstrates that Black 
NLST participants benefitted more from LDCT screening in terms of lung cancer specific and 
all cause mortality than White participants. The association between African---American 
participants and probable increased socioeconomic deprivation highlights the importance of 
good access to healthcare in low SES groups. The use of risk prediction scores and 
recruitment strategies that value racial origin are likely to gain increasing importance. By 
increasing our understanding of racial differences in the recruitment, adherence and efficacy 
of screening, we can not only improve the cost---effectiveness of lung cancer screening but 
also improve access to healthcare in individuals from minority groups.
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